SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid controversy over a proposed premium API service that would provide investors with early access to Donald Trump's social media posts. The stock remains a focal point for intense community debate, with users sharply divided over the company's business practices, the platform's potential for insider trading, and the political rhetoric surrounding election integrity.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is experiencing significant market interest driven by heavy trading volume and community speculation regarding upcoming regulatory catalysts, potential institutional accumulation, and long-term expansion goals for its TIL platform. Investors are actively debating the timing of a possible breakout as they weigh the stock's recent performance against expectations for future pipeline data and strategic business developments.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as investors weigh strong underlying business growth and rising institutional ownership against persistent price volatility and short-selling pressure ahead of the upcoming earnings report. The community remains deeply divided, with bulls highlighting the stock's long-term potential and expanding financial ecosystem, while bears point to past share dilution and frustrating performance as key reasons for skepticism.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending as investors reassess the company's growth trajectory and valuation following a significant price drawdown, with many in the community debating whether current levels present a long-term buying opportunity. Market participants are actively discussing the impact of slowing procedure growth, increased competition, and broader sector-wide pressure on this high-multiple stock.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

GameStop is trending following CEO Ryan Cohen's aggressive pursuit of eBay, an unsolicited $56 billion takeover attempt that the target's board has officially rejected. Investors are actively debating the viability of the deal, the impact of potential share dilution, and whether Cohen's strategy of forcing a hostile acquisition will succeed in unlocking long-term value.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is facing significant selling pressure as investors reprice high-growth nuclear stocks amid concerns over execution risk, delayed milestones, and a broader cooling of AI-related market sentiment. Community discussion is heavily divided between vocal critics pointing to the company's lack of revenue and persistent insider selling, and optimistic retail investors viewing the current valuation as an oversold entry point for a long-term infrastructure play.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is gaining significant investor attention driven by optimism surrounding their lead oral drug candidate, soquelitinib, and its potential to disrupt the immunology and oncology markets. While the community is actively debating the company's long-term valuation and buyout potential, sentiment is divided between bulls who point to institutional accumulation and positive clinical signals, and bears who express concerns over clinical trial timelines and intense sector competition.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is facing intense selling pressure as investors speculate on potential equity dilution, despite recent clinical updates and FDA Fast Track designation for its lead KRAS G12D candidate. While the community remains divided between long-term optimism regarding the pipeline's potential and frustration over poor stock performance, current discussions are heavily focused on the need for non-dilutive financing or a strategic partnership to stabilize value.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to heightened community speculation surrounding the company's upcoming regulatory filings, anticipation of data updates at the ASCO conference, and investor excitement regarding the potential for clinical trial partnerships or an eventual buyout. The community remains focused on the company's progress in expanding trial enrollment and the high-stakes potential of its breast cancer immunotherapy, viewing recent price volatility as a shakeout for retail holders while maintaining long-term confidence in the CEO's execution.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is sparking intense debate among investors as it consolidates near multi-year lows, with some market participants viewing current levels as a major accumulation opportunity ahead of an anticipated bull cycle. The community remains deeply divided, balancing technical theories of a potential squeeze against skepticism regarding the asset's relative performance compared to the broader crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026...

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income...

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption...

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Why Is IOVA Stock Falling Today?

Equity

During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Extremely Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Investors are closely watching the $5 share price threshold, viewing it as a critical psychological and institutional level to escape penny stock status.

Heightened speculation about a potential short squeeze is intensifying as traders track heavy volume and watch for price action that forces bearish traders to cover.

Anticipation is building for the upcoming earnings call, with longs optimistic about potential revenue beats and institutional interest increasing ahead of the event.

The community continues to rally behind the clinical potential of tumor-infiltrating lymphocyte (TIL) therapy for treating solid tumors like NSCLC.

Current Price	$5.00
Prev Close	$4.66
Open	$4.54
Dividend Yield	0.00%
50-Day Moving Average	$4.03
Beta	1.73
Avg. Volume	13.74M
PE Ratio	-5.26

52-Week High	$5.63
52-Week Low	$1.76
Market Capitalization	$2.08B
EPS (Annual)	-$1.09
Price to Book	3.04
Revenue Per Employee	$270,258.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVAIovance Biotherapeutics Inc

Latest IOVA News